#London #United Kingdom #Swarm Oncology #Cellex #T-Cell Therapy

Strategic Alliance to Promote Innovative Cancer Treatments

Swarm Oncology Ltd., a pioneering biotech firm known for developing innovative T-cell therapies, has announced a strategic partnership with Cellex Cell Professionals GmbH, a leading contract development and manufacturing organization (CDMO). This collaboration aims to advance cutting-edge therapies for the treatment of solid tumors, addressing current limitations in cancer care and striving for lasting remission among patients.

Addressing Unmet Needs in Oncology

Despite significant advancements in oncological treatments, over 82% of patients with advanced metastatic cancer still succumb to their illness, illustrating the pressing need for more effective options. Existing immunotherapies often fall short of delivering substantial survival benefits due to challenges like T-cell exhaustion, inadequate cell numbers, and limited antigen diversity.

Swarm Oncology's proprietary platform, known as Swarm-T, stands apart. By integrating in vivo immune priming and patented ex vivo manufacturing techniques, it generates highly potent and non-exhausted polyclonal T-cells. Unlike conventional approaches, Swarm-T actively confronts solid tumors with a robust and sustained immune response.

Role of Cellex in the Partnership

Under the terms of the partnership, Cellex will provide starting cell material and oversee process transfer, ensuring manufacturing adherence to good manufacturing practices (GMP) and quality control protocols. Furthermore, Cellex will offer regulatory compliance support and specialized infrastructure to facilitate the rapid advancement of Swarm's therapies, aiming for clinical trials initiation in 2026. This partnership aspires to speed up clinical timelines, reduce manufacturing bottlenecks, and enhance scalability, ultimately making these innovative T-cell therapies available to patients suffering from solid tumors.

Quotes from Leadership

Martin Olin, CEO of Swarm, remarked: "Swarm's mission is to transform immunotherapy by overcoming its limitations and achieving long-term remission for solid cancer patients. With Cellex's extensive expertise in cell collection, therapy manufacturing, and regulatory compliance, we can ensure a seamless high-quality manufacturing process, propelling clinical development to deliver life-changing treatments reliably and at scale."

Echoing this sentiment, Prof. Dr. Gerhard Ehninger, CEO of Cellex, stated: "We are excited to support Swarm's mission to drive innovation in solid tumor treatment. Our state-of-the-art facilities and over a decade of experience in T-cell therapies equip us well to expedite the delivery of transformative therapies to clinics efficiently."

About Swarm Oncology

Founded by Professor John Campbell, a renowned immunologist, Swarm Oncology is on a mission to develop powerful new T-cell therapies that address the significant shortcomings of current immunotherapeutic approaches, with the ultimate goal of achieving complete remission of solid tumors. More information can be found on their website: www.swarmoncology.bio.

About Cellex Cell Professionals

Cellex Cell Professionals is a premier full-service contract development and manufacturing organization, specializing in cellular and gene therapy production. Based in Cologne, Germany, Cellex has over ten years of experience in manufacturing compliant autologous and allogeneic cell therapies. They partner with leading pharmaceutical and biotech companies, supporting clinical and commercial manufacturing as well as providing customized raw materials for research and therapeutic use. To learn more, visit www.cellex.me/en.

Conclusion

This strategic partnership sets the stage for groundbreaking advancements in cancer treatment through innovative T-cell therapies. By combining Swarm Oncology's pioneering research with Cellex's manufacturing expertise, the companies aim to bring hope to patients battling solid tumors. As the sectors of biotechnology and manufacturing continue to evolve, collaborations like this could help forge a new path in the fight against cancer.